Peptide Bioregulator and Nickel Show Protective Effects in Breast Cancer Cells

Ductal breast cancer (DBC) is a prevalent form of breast cancer often associated with significant genomic instability, manifesting as structural aberrations, aneuploidy (abnormal chromosome numbers), and fragile sites within cells. This instability is believed to stem from changes in chromatin (the complex of DNA and proteins that forms chromosomes) and specific epigenetic variations across the genome. Understanding and correcting this instability is crucial for developing more effective treatments. This research aimed to determine if a specific peptide bioregulator and nickel ions could exert a correctional influence on the genomic instability observed in cells from DBC patients.

The study confirmed that DBC patients exhibit a high level of genome instability, which is a direct consequence of altered chromatin states. This instability was found to involve specific epigenetic variations in both heterochromatic and euchromatic regions of the genome. The used tests made it possible to conclude that this form of cancer subordinates to specific epigenetic variation. The peptide bioregulator Ala-Glu-Asp-Gly and nickel ions, when applied to the ductal breast cancer patient cell cultures, demonstrated a protective effect against this genomic instability. This protective action suggests a potential for these agents to stabilize the genome, counteracting the observed aberrations and fragile sites. The findings indicate that both agents, individually and in combination, can positively influence genome stability in these cancer cells.